Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hugo Castro

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2019
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host DiseaseJuan Montoro, Izaskun Ceberio, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsHugo Castro-Malaspina, Ann A Jabubowski, Esperanza B Papadopoulos, et al.
Cytotherapy|February 16, 2024
Proteomics of serum-derived extracellular vesicles are associated with the severity and different clinical profiles of patients with COVID-19: An exploratory secondary analysisAdriana F Paes Leme, Sami Yokoo, Ana Gabriela C Normando, et al.
Bone Marrow Transplantation|October 25, 2019
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34<sup>+</sup> selected graftRichard J Lin, Matias Sanchez, Kamal Abbi, et al.
The Lancet. Oncology|March 28, 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyPeter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2007
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failureJoseph H Chewning, Hugo Castro-Malaspina, Ann Jakubowski, et al.
Leukemia & Lymphoma|January 12, 2017
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplantJenna D Goldberg, Junting Zheng, Ravin Ratan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2019
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34<sup>+</sup> Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Valkal Bhatt, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 7, 2018
CD34<sup>+</sup> Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Pere Barba, Rodrigo Martino, Qin Zhou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2015
CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased RelapseRoni Tamari, Stephen S Chung, Esperanza B Papadopoulos, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2019
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host DiseaseJuan Montoro, Izaskun Ceberio, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2008
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsHugo Castro-Malaspina, Ann A Jabubowski, Esperanza B Papadopoulos, et al.
Cytotherapy|February 16, 2024
Proteomics of serum-derived extracellular vesicles are associated with the severity and different clinical profiles of patients with COVID-19: An exploratory secondary analysisAdriana F Paes Leme, Sami Yokoo, Ana Gabriela C Normando, et al.
Bone Marrow Transplantation|October 25, 2019
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34<sup>+</sup> selected graftRichard J Lin, Matias Sanchez, Kamal Abbi, et al.
The Lancet. Oncology|March 28, 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyPeter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 24, 2007
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failureJoseph H Chewning, Hugo Castro-Malaspina, Ann Jakubowski, et al.
Leukemia & Lymphoma|January 12, 2017
Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplantJenna D Goldberg, Junting Zheng, Ravin Ratan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2019
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34<sup>+</sup> Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Valkal Bhatt, Patrick Hilden, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 7, 2018
CD34<sup>+</sup> Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Pere Barba, Rodrigo Martino, Qin Zhou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 19, 2015
CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased RelapseRoni Tamari, Stephen S Chung, Esperanza B Papadopoulos, et al.
Pageof 9